WAVEMAN · COMPANY

GOSS · Gossamer Bio, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

GOSS

Name: Gossamer Bio, Inc. (GOSS) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Gossamer Bio, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001728117

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-57.7%

XBRL, annual

NET MARGIN

-351.5%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

91 funds added or opened last quarter

more than 62% of Pharma & Biotech

REVENUE

-57.7% year over year

below 85% of Pharma & Biotech

MARGIN

-351.5% net margin

below 80% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

19.4% of shares outstanding short · 1.5 days to cover · settled 2026-07-31

more than 95% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

91 funds added or opened positions in the latest 13F quarter, of 171 holders.

D. E. Shaw Valence Portfolios, L.L.C. disclosed a 5%+ stake (9.0%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -93.2%

-93.2%12M

13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows 91 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Gossamer Bio, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Milligan Sandra

Director

BUY

2025-08-19

26,050.0

$50.0K

Aranda Richard

Chief Medical Officer

SELL

2024-06-24

1,908.0

$1.3K

Hasnain Faheem

President & CEO

BUY

2024-06-21

372,000.0

$249.2K

Giraudo Bryan

COO/CFO

BUY

2024-06-18

100,000.0

$59.0K

Smith Robert Paul JR

Chief Commercial Officer

BUY

2024-06-17

25,000.0

$15.0K

42 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 37 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

D. E. Shaw & Co., Inc.

40,959,285.0 sh

$6.7M

683 Capital Management, LLC

39,198,868.0 sh

$6.5M

DeepCurrents Investment Group LLC

37,665,073.0 sh

$6.0M

Context Capital Management, LLC

28,946,459.0 sh

$4.8M

Worth Venture Partners, LLC

25,017,881.0 sh

$4.1M

5%+ owners

13D = intent to influence · 13G = passive

D. E. Shaw Valence Portfolios, L.L.C.

ACTIVIST 13D · 2026-06-11

9.0%

D. E. Shaw & Co., L.L.C.

ACTIVIST 13D · 2026-06-11

9.4%

D. E. Shaw & Co., L.P.

ACTIVIST 13D · 2026-06-11

9.5%

David E. Shaw

ACTIVIST 13D · 2026-06-11

9.5%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Virtus Biotech Clinical Trials Etf

$28.2K POSITION · AS OF 2026-04-30

0.1%

PACE Small/Medium Co Growth Equity Investments

$53.5K POSITION · AS OF 2026-04-30

0.0%

iShares Micro-Cap ETF

$164.3K POSITION · AS OF 2026-03-31

0.0%

Eventide Small Cap ETF

$2.7K POSITION · AS OF 2026-04-30

0.0%

Clearwater Select Equity Fund

$37.5K POSITION · AS OF 2026-03-31

0.0%

Invesco Nasdaq Biotechnology ETF

$5.5K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Faheem Hasnain

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$2.3M

$9.2M

$1.2M

+43%

—

2024

$2.0M

$1.9M

$1.1M

-58%

—

2023

$2.1M

$1.6M

$1.3M

-58%

—

2022

$7.3M

-$1.9M

$2.9M

-78%

—

2021

$4.8M

$6.3M

$2.2M

+17%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$48.5M	$114.7M	$0	$0
OPERATING INCOME	$-170.7M	$-59.9M	$-183.8M	$-218.6M
NET INCOME	$-170.4M	$-56.5M	$-179.8M	$-229.4M
EPS (DILUTED)	-0.75	-0.25	-1.18	-2.71
OPERATING CASH FLOW	$-171.3M	$-3.5M	$-159.2M	$-187.0M
CASH	$37.7M	$46.1M	$32.1M	$112.0M
LONG-TERM DEBT	—	$0	$814.0K	$12.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE